Sinil Pharmaceutical Co. Ltd
Sinil Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in South Korea and internationally. It offers pharmaceutical products for various indications, such as pain reliever, anti-inflammatory, hyperlipidemia, skin disease, and folic acid deficiency; and general/specialty drugs, veterinary drugs, and OEM products for various diseases. The company also provides cosmetics, incl… Read more
Sinil Pharmaceutical Co. Ltd (012790) - Total Liabilities
Latest total liabilities as of September 2025: ₩18.23 Billion KRW
Based on the latest financial reports, Sinil Pharmaceutical Co. Ltd (012790) has total liabilities worth ₩18.23 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sinil Pharmaceutical Co. Ltd - Total Liabilities Trend (2014–2024)
This chart illustrates how Sinil Pharmaceutical Co. Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Sinil Pharmaceutical Co. Ltd Competitors by Total Liabilities
The table below lists competitors of Sinil Pharmaceutical Co. Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Da Ming International Holdings Limited
F:DM7
|
Germany | €14.23 Billion |
|
DGL Group Ltd
AU:DGL
|
Australia | AU$280.59 Million |
|
VLS Finance Limited
NSE:VLSFINANCE
|
India | ₹2.90 Billion |
|
Roularta
BR:ROU
|
Belgium | €139.22 Million |
|
Kamdhenu Limited
NSE:KAMDHENU
|
India | ₹618.81 Million |
|
High Co. SA
PA:HCO
|
France | €93.19 Million |
|
Samick Music I
KO:002450
|
Korea | ₩233.95 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down Sinil Pharmaceutical Co. Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.63 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sinil Pharmaceutical Co. Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sinil Pharmaceutical Co. Ltd (2014–2024)
The table below shows the annual total liabilities of Sinil Pharmaceutical Co. Ltd from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩19.36 Billion | +10.20% |
| 2023-12-31 | ₩17.56 Billion | -10.18% |
| 2022-12-31 | ₩19.55 Billion | +23.94% |
| 2021-12-31 | ₩15.78 Billion | -8.94% |
| 2020-12-31 | ₩17.33 Billion | +4.42% |
| 2019-12-31 | ₩16.59 Billion | +47.90% |
| 2018-12-31 | ₩11.22 Billion | -3.20% |
| 2017-12-31 | ₩11.59 Billion | +6.69% |
| 2016-12-31 | ₩10.86 Billion | +19.49% |
| 2015-12-31 | ₩9.09 Billion | +0.39% |
| 2014-12-31 | ₩9.06 Billion | -- |